Hikal Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8zi5eziqtgiz3p5xgbzzcyrk.pdf

Key Takeaways


Demand Environment & Volume Reality

Sameer Hiremath: "We expect prices to bottom out, elevated inventory levels to subside and demand likely to pick up at the end of this financial year, resulting in improvement in operational profitability quarter-on-quarter going forward."

Margin Bridge & Recovery Thesis

Sameer Hiremath: "We expect H2 and the new products which are kicking in and all the CDMO part to come back from Q3-Q4. And as I have been saying, we expect quarter-on-quarter improvement. And towards the end of the year, we'll get back towards steady state."

Capex, Capacity & the Growth Bet


CDMO Pipeline & Pharma Levers


Balance Sheet & Funding


Guidance & Commitments

CommitmentSpecificsTimeline
Demand recoveryPrices bottom out, inventory subsides, demand picks upEnd of this financial year (Q4 FY24)
Crop Protection normalizationChannel destocking ends, volumes begin to recoverQ4 FY24 onward
CDMO recoveryCustomers restock, CDMO proportion rises from current 30%Q3-Q4 FY24
Margin improvementSequential QoQ improvement back toward steady stateH2 FY24, exit toward steady state by year-end
API launches3-4 products launched from a pipeline of 8-10During FY24
Animal Health validation batchesSubmission of validation batches for several new productsOver next 4-6 quarters
Animal Health revenue contributionRegistrations complete, revenue startsH2 FY26 onward
Capex completionOngoing projects finished, assets enter mainstream productionAround April-March of next year
Long-term revenue targetTop line of INR 3,500-4,000 croresBy FY26-FY27

Key Metrics

MetricQ2 FY24
Revenue₹435 cr, +12% QoQ
EBITDA₹57 cr, +14% QoQ
EBITDA margin13.2%, +73 bps YoY
Contribution margin~46% (overall company)
Pharma revenue₹270 cr, +20% QoQ
Pharma EBIT margin4.3%
Crop Protection revenue₹165 cr
Crop Protection EBIT margin13.3%
Crop Protection EBIT growth~28% QoQ
API to CDMO ratio (H1)70:30, vs historical ~60:40
Total debt₹778 cr, in line with ₹779 cr in H1 last year
Cost of funds8.7%, up from 6.7%
Debt-to-equity ratio0.61
FY24 capex plan₹200 cr, ₹100 cr completed, ₹100 cr left
CWIP capitalization expected this year₹480–490 cr
Crop Protection volume growth (H1)-26% YoY
Pharma volume growth (H1)+4% YoY
Company volume growth (H1)-16% YoY, driven by Crop Protection
Customer audits increase1.5x over last 4 years